HOME >> BIOLOGY >> NEWS
When One Gene Has Two Roles, Its Second Function May Be Missed

these are clearly the most distant regulatory elements that have been identified in any structural gene. It's a further demonstration of why we need to map and sequence the entire genome if we hope to understand how these elements work."

Derangements of GATA-2 expression could underlie any of a wide range of human conditions. The researchers note that developmental abnormalities of the genitourinary system are estimated to affect 10 percent of the population, accounting for one-third of all congenital malformations and 40 percent of kidney diseases.

The researchers also note that the general approach of trying to replace a missing function in mice that have had a gene knocked out may reveal unknown functions of that gene at later developmental stages.

Other authors on the EMBO Journal paper include graduate student Yinghui Zhou and postdoctoral fellows Kim-Chew Lim and Ko Onodera, all of Northwestern; Stuart H. Orkin, Leland Fikes Professor of Pediatric Medicine, and postdoctoral researcher Fong-Ying Tsai of Harvard Medical School; and Masayuki Yamamoto, professor of molecular and developmental biology, and postdoctoral researchers Satoru Takahashi, Naoko Minegishi and Jun Ohta of the University of Tsukuba.

The research was funded by the National Institute of General Medical Sciences, one of the National Institutes of Health.


'"/>

Contact: Bill Burton
b-burton@nwu.edu
847-491-3115
Northwestern University
12-Nov-1998


Page: 1 2 3

Related biology news :

1. Second call for proposals for the European Young Investigator Award
2. Second generation targeted antibodies - Its all in the binding
3. Secondary complications and restoration of function in SCI
4. Second EMBO International Practical Workshop for Science Teachers
5. NTP-CERHR announces the Second Phthalates Expert Panel Meeting to be held December 15-17, 1999
6. In Logged Forests, Hunting of Wildlife Becomes Deadly Second Harvest
7. Iron Supplemented Formula Milk Should Be Free For Inner City Children Into Their Second Year Of Life
8. Oregon Scientists Discover A Second Blood-Brain Barrier; Important Finding For Patients With Brain Cancers And Neurological Disorders
9. Phase III Results Suggest Potent Antiviral Activity For Vertex And Glaxo Wellcomes Second-Generation HIV Protease Inhibitor Agenerase TM
10. The Second Visible Human Project Conference
11. Researchers Take A Second Look At Homocysteines Link To Heart Disease

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: When One Gene Has Two Roles Its Second Function May Missed

(Date:5/7/2015)... , May 7, 2015 ... sensors, FPC1022 and FPC1035, FPC,s smallest touch fingerprint ... are mainly considered for integration on the backside ... smartphone OEMs increased possibilities to integrate touch fingerprint ... size also improves possibilities for module manufacturers to ...
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... NOVATO, Calif. , May 21, 2015 /PRNewswire-USNewswire/ ... Orrin Hatch (R-UT) and Amy ... Product Extensions Now Accelerating Cures & Treatments, or ... 150 rare disease patient advocacy organizations, this bipartisan ... effective, and affordable medicines to rare disease patients ...
(Date:5/21/2015)... W. R. Grace & Co. ... Worms, Germany has received good manufacturing practice (GMP) ... International Pharmaceutical Excipient Council (IPEC) Foundation. ... SYLOID® FP brand of pharmaceutical grade excipient silica ... Curtis Bay, Maryland (USA) and Sorocaba, Brazil locations. ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ... "2015 Global Survey on Flow Cytometry Adoption Trends" ... primary goal of this research is to analyze ... Key information the survey seeks to collect include ... predominantly used applications for flow cytometers, respondents, most ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: